3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Dexamethasone
44
Lenalidomide
29
Bortezomib
23
daratumumab
22
pomalidomide
19
Cyclophosphamide
15
carfilzomib
14
Specimen Handling
14
Biopsy
14
Calcium Dobesilate
12
Magnetic Resonance Spectroscopy
10
talquetamab
9
isatuximab
9
Melphalan
8
iberdomide
7
fludarabine
7
belantamab mafodotin
6
dexamethasone acetate
5
dexamethasone 21-phosphate
5
auricularum
5
X-Rays
5
tocilizumab
4
selinexor
4
fludarabine phosphate
4
elotuzumab
4
Nuclear Medicine Department, Hospital
4
trametinib
3
dabrafenib
3
Whole-Body Irradiation
3
Thalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
cobimetinib
×
30 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled